Use of neuregulin-4 for treatment of inflammatory bowel disease and necrotizing enterocolitis
AssigneeChildren's Hospital Los Angeles
InventorMark R. Frey
Life of this patent
Estimating the term…
Abstract
The invention provides methods, pharmaceutical compositions and kits for treating, inhibiting and/or reducing the severity of inflammatory bowel disease and necrotizing enterocolitis in a subject in need thereof by administering an effective amount of a composition comprising an activator of ErbB4.
Claims22
A method for treating inflammatory bowel disease in a subject in need thereof comprising:
- a. providing a composition comprising an activator of ErbB4;
- and
- b. administering a therapeutically effective amount of the composition to the subject so as to treat inflammatory bowel disease.
A method for inhibiting inflammation-associated death of small intestinal and colonic epithelial cells comprising:
- a. providing a composition comprising an activator of ErbB4;
- and
- b. administering a therapeutically effective amount of the composition to the subject so as to inhibit inflammation-associated death of small intestinal and colonic epithelial cells.
A method for treating or inhibiting necrotizing enterocolitis in a subject in need thereof comprising:
- a. providing a composition comprising an activator of ErbB4;
- and
- b. administering a therapeutically effective amount of the composition to the subject so as to treat necrotizing enterocolitis.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A pharmaceutical composition comprising an activator of ErbB4 and a pharmaceutically acceptable carrier.
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.